← Back to Search

T Cell Depletion

1. CliniMACS CD3+/CD19+ depletion for Immunodeficiency (CliniMACs Trial)

Phase 2
Waitlist Available
Led By Nancy J Bunin, MD
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 100 days post transplant
Awards & highlights

CliniMACs Trial Summary

This trial is testing a new way to transplant stem cells from donors who are either unrelated or only partially matched to the patient. The goal is to reduce the risk of a severe side effect called graft vs. host disease.

Eligible Conditions
  • Immunodeficiency

CliniMACs Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~100 days post transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 100 days post transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Successful Engraftment

Side effects data

From 2017 Phase 2 trial • 93 Patients • NCT00579124
33%
Non-relapsed mortality
100%
80%
60%
40%
20%
0%
Study treatment Arm
AEs for Total Number of Participants: Stratum 2
AEs for Total Number of Participants: Stratum 1

CliniMACs Trial Design

2Treatment groups
Experimental Treatment
Group I: 2. CliniMACS CD3+/CD19+ depletionExperimental Treatment1 Intervention
Stratum 2. CliniMACS CD3+/CD19+ depletion: Haploidentical match 2 antigen and/or allele mismatched where one of the mismatches includes DRB1 For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum.
Group II: 1. CliniMACS CD3+/CD19+ depletionExperimental Treatment1 Intervention
6/6 or 8/8 matched (fully matched) 1 antigen or allele mismatched (mismatch at A or B or DRB1) 2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B). Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CliniMACs
2005
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Children's Hospital of PhiladelphiaLead Sponsor
708 Previous Clinical Trials
8,580,966 Total Patients Enrolled
Nancy J Bunin, MDPrincipal InvestigatorChildren's Hospital of Philadelphia
3 Previous Clinical Trials
260 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this therapy been federally approved in the United States?

"There is limited data supporting the safety of this treatment, as it is only in Phase 2 trials. No efficacy data exists currently."

Answered by AI

Are there still opportunities for people to participate in this clinical trial?

"The trial in question is not currently looking for participants, as evidenced by the lack of recent updates on clinicaltrials.gov. Although this particular study is not ongoing, there are 92 other trials that patients might be interested in."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion
Nancy Bunin 2005. "CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00579124.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top